CV301 in Bladder Cancer

Bavarian Nordic has entered a collaboration with Roche to evaluate the combination of CV301 and TECENTRIQ® (atezolizumab), Roche’s FDA-approved PD-L1 inhibitor, in a single-arm Phase 2 study in patients with locally advanced or metastatic urothelial carcinoma (bladder cancer) who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy, a patient population where TECENTRIQ has accelerated approval in the U.S.

The study’s primary endpoint is overall survival with secondary endpoints being ORR, DoR and PFS. The study is anticipated to initiate in the second quarter of 2018.